Abstract
ObjectiveTo compare the efficacy and the safety of recombinant human FSH (hFSH) with urinary hFSH for stimulating follicular development in women undergoing IVF-ET.DesignMulticenter, prospective, randomized, open, parallel group, clinical study.SettingEight European academic IVF units and one private IVF unit.PatientsInfertile female patients aged 18 to 38 years suffering from tubal disease, mild endometriosis, or unexplained infertility.InterventionsPretreatment with buserelin acetate was followed by recombinant or urinary hFSH treatment started at an initial dose of 225 IU FSH/d. Dose adjustment was allowed after 5 days of FSH. After administration of hCG, a standard IVF-ET procedure was performed.Main Outcome MeasuresFollicular development, oocyte retrieval, fertilized oocytes, duration and dose of FSH, and pregnancy. The hypothesis formulated before the study was that no difference was expected between the two FSH preparations.ResultsSixty patients were treated with recombinant hFSH and 63 with urinary hFSH. The mean number (±SD) of growing follicles (mean diameter >10 mm) was 10.3 ± 4.9 and 11.2 ± 5.2, of follicles (mean diameter > 14 mm) was 7.8 ± 3.6 and 9.2 ± 4.5, of retrieved oocytes was 9.3 ± 5.0 and 10.7 ± 5.3, and of fertilized oocytes was 5.6 ± 3.8 and 6.5 ± 4.3, for recombinant and urinary hFSH, respectively. The duration of FSH treatment was 9.9 ± 2.3 and 9.4 ± 1.8 days and the average total dose was 2270 ± 714 and 2095 ± 591 IU of FSH, for recombinant and urinary hFSH, respectively. Thirteen pregnancies were recorded in the recombinant hFSH group and 11 in the urinary hFSH group. Nine patients delivered 13 live infants in the recombinant hFSH group and eight delivered 13 live infants in the urinary hFSH group. In terms of safety, no difference was recorded between the groups and no anti-FSH antibodies were found in any of the patients.ConclusionsThis clinical study shows that recombinant hFSH is as safe and effective as urinary hFSH in stimulating ovarian follicular development.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
